By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Acetylon Pharmaceuticals 

Boston  Massachusetts    U.S.A.
Phone: 617-435-2664 Fax: n/a




Company News
Acetylon Pharmaceuticals Publishes New Mechanism For The Treatment Of Sickle Cell Disease/Beta-Thalassemia With Selective HDAC1/2 Inhibition In Plos One 5/4/2016 8:29:09 AM
Acetylon Pharmaceuticals Announces The Presentation Of Preclinical Data At AACR Supporting The Use Of Selective HDAC6 Inhibition To Modulate Chronic Lymphocytic Leukemia (CLL) Immunobiology 4/20/2016 11:32:03 AM
Acetylon Pharmaceuticals Presents Data From Three Phase Ib Studies Of Ricolinostat (ACY-1215) For The Treatment Of Lymphoma And Multiple Myeloma 12/7/2015 10:36:02 AM
Acetylon Pharmaceuticals Presents Data On The Use Of HDAC 6 Inhibitors Ricolinostat (ACY-1215) And ACY-241 In Combination With Pomalidomide For The Treatment Of Multiple Myeloma 12/7/2015 10:18:33 AM
Acetylon Pharmaceuticals Presents Data On The Pharmacokinetics And Hbe/Hbg Hemoglobin Induction Following Once Daily Dosing Of An Oral HDAC1,2 Inhibitor In Animal Models 12/7/2015 10:17:20 AM
Acetylon Pharmaceuticals’s Oral Selective HDAC6 Inhibitor ACY-241 Enhances Anti-Tumor Activity Of Paclitaxel In Preclinical Solid Tumor Models 11/6/2015 8:10:15 AM
Acetylon Pharmaceuticals To Present At BioPharm America 2015 9/14/2015 3:10:26 PM
Acetylon Pharmaceuticals Presented Positive Preliminary Data From Phase 1b/2 Trial Of Ricolinostat In Combination With Pomalyst As Potential Oral Treatment For Patients With Multiple Myeloma 6/16/2015 11:47:06 AM
Acetylon Pharmaceuticals Presents Data On Synergistic Activity Of Selective HDAC6 Inhibition In Preclinical Models Of Multiple Myeloma And Mantle Cell Lymphoma At The AACR Annual Meeting 4/22/2015 8:44:05 AM
Acetylon Pharmaceuticals Announces Preclinical Anti-Cancer Activity Of Selective HDAC1/2 Inhibitors In Neuroblastoma And Acute Myeloid Leukemia 4/20/2015 1:05:32 PM